Jefferies Group reissued their buy rating on shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) in a research report released on Saturday morning. The brokerage currently has a $63.00 price objective on the stock.

Other analysts also recently issued reports about the stock. KeyCorp reissued a buy rating on shares of PRA Health Sciences in a research report on Friday, November 4th. Zacks Investment Research downgraded shares of PRA Health Sciences from a buy rating to a hold rating in a report on Wednesday, November 9th. Citigroup Inc. upped their price objective on shares of PRA Health Sciences from $55.00 to $66.00 and gave the stock a buy rating in a report on Thursday, September 22nd. Credit Suisse Group reaffirmed a hold rating and set a $50.00 price objective on shares of PRA Health Sciences in a report on Thursday, November 3rd. Finally, TheStreet raised shares of PRA Health Sciences from a hold rating to a buy rating in a report on Monday, November 14th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $56.71.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Shares of PRA Health Sciences (NASDAQ:PRAH) opened at 57.59 on Friday. The company has a market cap of $3.54 billion, a P/E ratio of 44.71 and a beta of 0.53. The company’s 50 day moving average is $54.72 and its 200-day moving average is $51.48. PRA Health Sciences has a 12 month low of $35.60 and a 12 month high of $60.96.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, November 2nd. The company reported $0.64 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.64. The company earned $399.80 million during the quarter, compared to the consensus estimate of $394.87 million. PRA Health Sciences had a net margin of 4.86% and a return on equity of 21.25%. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.52 earnings per share. Analysts expect that PRA Health Sciences will post $2.46 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “PRA Health Sciences, Inc. (PRAH) Receives Buy Rating from Jefferies Group” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be read at http://www.watchlistnews.com/pra-health-sciences-inc-prah-receives-buy-rating-from-jefferies-group/1061414.html.

A number of hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in shares of PRA Health Sciences by 9,368.8% in the second quarter. JPMorgan Chase & Co. now owns 91,374 shares of the company’s stock worth $3,815,000 after buying an additional 90,409 shares during the period. State Board of Administration of Florida Retirement System increased its stake in shares of PRA Health Sciences by 30.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 12,846 shares of the company’s stock worth $536,000 after buying an additional 3,020 shares during the period. California Public Employees Retirement System increased its stake in shares of PRA Health Sciences by 22.6% in the second quarter. California Public Employees Retirement System now owns 15,200 shares of the company’s stock worth $635,000 after buying an additional 2,800 shares during the period. Swiss National Bank increased its stake in shares of PRA Health Sciences by 20.7% in the second quarter. Swiss National Bank now owns 54,258 shares of the company’s stock worth $2,266,000 after buying an additional 9,318 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of PRA Health Sciences by 23.6% in the second quarter. Bank of New York Mellon Corp now owns 173,821 shares of the company’s stock worth $7,260,000 after buying an additional 33,229 shares during the period. 99.80% of the stock is owned by hedge funds and other institutional investors.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

5 Day Chart for NASDAQ:PRAH

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.